The Insider Report: Get Ready for the Upcoming Buying Opportunity During the Next Market Dip
Market Overview: The stock market is experiencing turbulence, with the Nasdaq down 2.74% and a notable rotation into healthcare, which is currently the only sector showing strong opportunities. The crypto market is facing significant challenges, indicating a critical juncture ahead.
Dianthus Therapeutics: Dianthus Therapeutics (DNTH) is a clinical-stage biotech company focused on innovative therapies for autoimmune diseases, showing potential for a 95% return. Despite a high Price-to-Sales ratio, recent technical patterns suggest an upward momentum.
Daqo New Energy: Daqo New Energy (DQ), a leading polysilicon manufacturer for solar products, presents a 78% return potential. The company is well-positioned to benefit from the growing renewable energy sector, with strong operational resilience and strategic expansion plans.
Arcus Biosciences: Arcus Biosciences (RCUS) is developing advanced cancer therapies, with a 45% return potential. The company is backed by significant partnerships and funding, allowing it to aggressively pursue its pipeline while navigating the biotech landscape.
Trade with 70% Backtested Accuracy
Analyst Views on DQ
About DQ
About the author

Daqo New Energy Estimates 2025 Net Loss of RMB 1.0-1.3 Billion
- Net Loss Estimate: Daqo's subsidiary Xinjiang Daqo estimates a net loss of RMB 1.0 to 1.3 billion for FY2025, an improvement from the RMB 2.7 billion loss in FY2024, indicating gradual recovery amidst challenges.
- Shareholder Impact: The estimated net loss will directly affect approximately 72.8% of Daqo's equity interest in Xinjiang Daqo, highlighting ongoing concerns regarding the potential threat to the company's overall financial health despite the reduction in losses.
- Financial Reporting Discrepancy: Xinjiang Daqo's financial results are prepared under PRC GAAP, while Daqo's consolidated results are reported under U.S. GAAP, which may lead to investor misunderstandings regarding the company's overall financial condition.
- Investor Caution: The company advises investors to exercise caution regarding the preliminary loss estimate, as actual results may vary significantly from this estimate, underscoring the uncertainty and risks surrounding future financial performance.

Daqo New Energy Estimates 2025 Net Loss of RMB 1.3 Billion
- Net Loss Estimate: Daqo's subsidiary Xinjiang Daqo estimates a net loss of RMB 1.0 to 1.3 billion for FY2025, an improvement from the RMB 2.7 billion loss in FY2024, indicating gradual recovery amidst challenges.
- Equity Structure: Daqo New Energy owns approximately 72.8% of Xinjiang Daqo, highlighting the close relationship between its financial performance and that of its subsidiary, suggesting future profitability will be influenced by Xinjiang Daqo's results.
- Financial Reporting Differences: The loss estimate is prepared under PRC GAAP, while Daqo's consolidated results are reported under U.S. GAAP, illustrating the differences in financial transparency and reporting standards between the two.
- Investor Caution: The company advises investors to exercise caution regarding the preliminary loss estimate, as actual results may vary significantly, emphasizing the uncertainty and risks surrounding future financial performance.






